Letrozol Glenmark 2,5 mg

Description

Indications

Early estrogen receptor-expressing breast cancer in postmenopausal women – as adjuvant therapy;
early breast cancer in postmenopausal women after completion of standard adjuvant therapy with tamoxifen – as extended adjuvant therapy;
advanced hormone-dependent breast cancer in postmenopausal women – first-line therapy;
advanced breast cancer in postmenopausal women (natural or artificially induced) who have received prior anti-estrogen therapy.
Use during pregnancy and lactation
Contraindicated use during pregnancy and lactation (breastfeeding).

Contraindications

• Endocrine conditions specific to the reproductive period;
  pregnancy;
• lactation (breastfeeding);
• childhood (efficacy and safety in children has not been established);
• hypersensitivity to the components of the drug.

Caution: the drug should be used in cases of lactase deficiency, lactase intolerance, glucose-galactose malabsorption syndrome. There are no data on the use of letrozole in patients with a CK < 30 ml/min (the ratio of potential risk to expected treatment effect should be carefully considered before prescribing the drug to such patients).